| CAMBRIDGE, Mass., April 16/ PRNewswire/ -- Alnylam Pharmaceuticals, Inc., the leading
therapeutic RNA interference (RNAi) company, today announced the appointment of two
senior executives to the company's management team.
Victor E. Kotelianski, M.D., Ph.D., has been appointed to the position of Vice President
of Research and David M. Konys has been appointed to the position of Vice President of
Corporate Development and Operations.
"Alnylam is very pleased to welcome Dr. Kotelianski and Mr. Konys, both of whom are highly respected in their fields," said Dr. John Maraganore, President and CEO of Alnylam. "With their broad biotech expertise, Dr. Kotelianski and Mr. Konys will significantly strengthen Alnylam's capabilities as we continue to build our team."
Dr. Kotelianski was formerly Distinguished Investigator, Director of Biological Research at Biogen, Inc., where he has worked since 1994. In his prior experience, Dr. Kotelianski served as Director of Research, Institut National de la Sante et de la Reserche Medicale (INSERM) in Paris, France, and was as a leading research scientist at the Academy of Medical Sciences in Moscow. In his role as Vice President of Research at Alnylam, Dr. Kotelianski will have responsibility for all of Alnylam's research activities in biology and pharmacology.
Mr. Konys was the former Vice President of Corporate Development at Ingenium Pharmaceuticals AG, and prior to that, had over 15 years of experience at Biogen, Inc., where he was the 1995 recipient of the Chairman's Award. During his career, Mr. Konys has been responsible for a wide array of activities related to the building and expansion of growing biotech companies, including intellectual property management, facilities expansion, marketing, and licensing.
Alnylam Pharmaceuticals, Inc., is a leading company in the emerging field of RNA interference (RNAi) whose vision is to harness a revolution in biology for human healthTM. Over the last several years, RNAi has been discovered as a fundamental cellular mechanism for gene silencing. Alnylam has assembled the leading group of academic scientists in the field of RNAi as founders and advisors. The intellectual property of the Alnylam's founders has allowed the company to enter this field with a leadership position. Alnylam's focus is to discover, develop, and commercialize therapeutic products based on RNAi for a broad range of therapeutic indications including viral infection, oncology, and autoimmune disease. The company's mission is to lead research in the field of RNAi, to build the leading pipeline of RNAi-based therapeutics, and to emerge as business leaders.
Alnylam is headquartered in Cambridge, MA. The company was founded in 2002 with investment from leading venture capital firms: Polaris Venture Partners, Cardinal Partners, Atlas Venture Partners, and ARCH Venture Partners. Additional information is available on the Company's web site at http://www.alnylam.com